Jonathan Benjamin Gill

Jonathan Benjamin Gill

Auto-generated profile, based on publicly available information

Jonathan Benjamin Gill

The University of Texas MD Anderson Cancer Center 1 Division of Pediatrics, Children’s Cancer Hospital Houston, Texas

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JGJonathan Gill
Jonathan Gill
RGRichard Gorlick
Richard Gorlick

8 December 2022 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
HBHannah Beird
Hannah Beird
SBStefan S. Bielack
Stefan S. Bielack
AFAdrienne M. Flanagan
Adrienne M. Flanagan
JGJonathan Gill
Jonathan Gill
Dominique HeymannDominique Heymann
Dominique Heymann
RGRichard Gorlick
Richard Gorlick

21 March 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YWYifei Wang
Yifei Wang
XTXiangjun Tian
Xiangjun Tian
WZWendong Zhang
Wendong Zhang
ZZZhongting Zhang
Zhongting Zhang
RLRossana Lazcano
Rossana Lazcano
RGRichard Gorlick
Richard Gorlick
Immunoconjugates targeting cell-surface antigens have demonstrated clinical activity to enable regulatory approval in several solid and hematologic malignancies. We hypothesize that a rigorous and comprehensive surfaceome profiling approach to identify osteosarcoma-specific cell-surface antigens can similarly enable development of effective therapeutics in this disease. Herein, we describe an integrated proteomic and transcriptomic surfaceome profiling approach to identify cell-surface proteins that are highly expressed in osteosarcoma but minimally expressed on normal tissues. Using this approach, we identified targets that are highly expressed in osteosarcoma. Three targets, MT1-MMP, CD276, and MRC2, were validated as overexpressed in osteosarcoma. Furthermore, we tested BT1769, an MT1-MMP–targeted Bicycle toxin conjugate, in osteosarcoma patient-derived xenograft models. The results showed that BT1769 had encouraging antitumor activity, high affinity for its target, and a favorable pharmacokinetic profile. This confirms the hypothesis that our approach identifies novel targets with significant therapeutic potential in osteosarcoma.

9 December 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
PHPooja Hingorani
Pooja Hingorani
MRMichael Roth
Michael Roth
YWYifei Wang
Yifei Wang
WZWendong Zhang
Wendong Zhang
JGJonathan B. Gill
Jonathan B. Gill
RGRichard Gorlick
Richard Gorlick
Membrane protein leucine–rich repeat containing 15 (LRRC15) is known to be expressed in several solid tumors including osteosarcoma. ABBV-085, an antibody–drug conjugate against LRRC15, conjugated to monomethyl auristatin E (MMAE), was studied in osteosarcoma patient-derived xenografts (PDXs) by the Pediatric Preclinical Testing Consortium (PPTC). LRRC15 expression data were obtained from PPTC RNA-sequencing data for the PDX models. The TARGET database was mined for LRRC15 expression in human osteosarcoma. Protein expression was confirmed via IHC in three PDX models. Seven osteosarcoma PDX models (OS1, OS9, OS33, OS34, OS42, OS55, and OS60) with varying LRRC15 gene expression were studied. ABBV-085 was administered at 3 mg/kg (OS33), 6 mg/kg (all seven PDXs), and 12 mg/kg (OS60) weekly for 4 consecutive weeks via intraperitoneal injection. Control cohorts included vehicle and an isotype MMAE-linked antibody. Tumor volumes and responses were reported using PPTC statistical analysis. OS1, OS33, OS42, OS55, and OS60 had high LRRC15 expression while OS9 and OS34 had low LRRC15 expression. ABBV-085 inhibited tumor growth in six of seven PDX models as compared with vehicle control and significantly improved event-free survival in five of seven models as compared with isotype controls. Two models showed maintained complete responses while all others showed progressive disease. Response correlated with LRRC15 expression. ABBV-085’s antitumor activity against osteosarcoma PDX suggests LRRC15 may be a rational target for pursuing clinical trials in patients with this disease.

1 June 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MTMatteo Trucco
Matteo Trucco
JBJulio C. Barredo
Julio C. Barredo
JGJohn Goldberg
John Goldberg
GLGilles M. Leclerc
Gilles M. Leclerc
GHGregory A. Hale
Gregory A. Hale
DRDamon R. Reed
Damon R. Reed

2 June 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
PHPooja Hingorani
Pooja Hingorani
WZWendong Zhang
Wendong Zhang
ZZZhongting Zhang
Zhongting Zhang
ZXZhaohui Xu
Zhaohui Xu
WWWei-Lien Wang
Wei-Lien Wang
RGRichard Gorlick
Richard Gorlick
HER2 is expressed in many pediatric solid tumors and is a target for innovative immune therapies including CAR-T cells and antibody–drug conjugates (ADC). We evaluated the preclinical efficacy of trastuzumab deruxtecan (T-DXd, DS-8201a), a humanized monoclonal HER2-targeting antibody conjugated to a topoisomerase 1 inhibitor, DXd, in patient- and cell line–derived xenograft (PDX/CDX) models. HER2 mRNA expression was determined using RNA-seq and protein expression via IHC across multiple pediatric tumor PDX models. Osteosarcoma (OS), malignant rhabdoid tumor (MRT), and Wilms tumor (WT) models with varying HER2 expression were tested using 10 mice per group. Additional histologies such as Ewing sarcoma (EWS), rhabdomyosarcoma (RMS), neuroblastoma (NB), and brain tumors were evaluated using single mouse testing (SMT) experiments. T-DXd or vehicle control was administered intravenously to mice harboring established flank tumors at a dose of 5 mg/kg on day 1. Event-free survival (EFS) and objective response were compared between treatment and control groups. HER2 mRNA expression was observed across histologies, with the highest expression in WT (median = 22 FPKM), followed by MRT, OS, and EWS. The relationship between HER2 protein and mRNA expression was inconsistent. T-DXd significantly prolonged EFS in 6/7 OS, 2/2 MRT, and 3/3 WT PDX models. Complete response (CR) or maintained CR (MCR) were observed for 4/5 WT and MRT models, whereas stable disease was the best response among OS models. SMT experiments also demonstrated activity across multiple solid tumors. Clinical trials assessing the efficacy of a HER2-directed ADC in pediatric patients with HER2-expressing tumors should be considered.